PMID- 28345816
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20180912
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Linking)
VI  - 56
IP  - 8
DP  - 2017 Aug
TI  - Germline variation in the 3'-untranslated region of the POU2AF1 gene is 
      associated with susceptibility to lymphoma.
PG  - 1945-1952
LID - 10.1002/mc.22652 [doi]
AB  - Genetic variations in certain genes may alter the susceptibility to lymphoma. We 
      searched electronic databases and selected candidate single-nucleotide 
      polymorphisms (SNPs) located within 3'-untranslated regions (3'-UTRs) that might 
      affect miRNA-binding ability in the 50 most dysregulated genes in lymphoma for 
      further study. We found that rs1042752-located in the 3'-UTR of POU2AF1, which 
      plays a vital role in lymphomagenesis-was significantly associated with lymphoma 
      risk in a case-control study with 793 patients and 939 controls. Compared with 
      individuals with the rs1042752TT genotype, those with the rs1042752CC genotype 
      had a higher risk of lymphoma (OR = 2.14, 95% CI: 1.55-2.95, P < 0.001), even in 
      stratified analysis for non-Hodgkin lymphoma (OR = 4.58, 95% CI: 2.38-8.81, 
      P < 0.001), B-cell lymphoma (OR = 4.89, 95% CI: 2.46-9.73, P < 0.001), T-cell 
      lymphoma (OR = 4.20, 95% CI: 1.76-10.05, P = 0.001), and Hodgkin lymphoma 
      (OR = 3.62, 95% CI: 1.25-10.46, P = 0.018). Similar results were also observed in 
      a recessive genetic model. Database findings suggested that rs1042752 might 
      affect the interaction of POU2AF1 mRNA with hsa-miR-633. Functional assays 
      confirmed that rs1042752C altered the binding site of hsa-miR-633 and increased 
      POU2AF1 expression in Ramos, HuT 102, and Jurkat E6-1 cell lines. These findings 
      demonstrate for the first time that functional polymorphism in the 3'-UTR of 
      POU2AF1 is associated with susceptibility, and that SNP interaction with 
      hsa-miR-633 affects gene expression and increases the risk of lymphoma.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Zhai, Kan
AU  - Zhai K
AUID- ORCID: 0000-0002-6495-3690
AD  - Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Chang, Jiang
AU  - Chang J
AD  - State Key Laboratory of Environment Health (Incubation), MOE (Ministry of 
      Education) Key Laboratory of Environment and Health, Ministry of Environmental 
      Protection Key Laboratory of Environment and Health (Wuhan) and School of Public 
      Health, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, China.
FAU - Hu, Jinlong
AU  - Hu J
AD  - Department of Oncology, People's Hospital of Zhengzhou University and Henan 
      Provincial People's Hospital, Zhengzhou, China.
FAU - Wu, Chen
AU  - Wu C
AD  - Department of Etiology and Carcinogenesis, Chinese Academy of Medical Science and 
      Peking Union Medical College, Cancer Institute and Hospital, Beijing, China.
FAU - Lin, Dongxin
AU  - Lin D
AD  - Department of Etiology and Carcinogenesis, Chinese Academy of Medical Science and 
      Peking Union Medical College, Cancer Institute and Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170419
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (3' Untranslated Regions)
RN  - 0 (MIRN633 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (POU2AF1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Trans-Activators)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Lymphoma/*genetics/metabolism
MH  - Male
MH  - MicroRNAs/genetics/metabolism
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - RNA, Messenger/genetics/metabolism
MH  - Trans-Activators/*genetics
OTO - NOTNLM
OT  - 3'-untranslated region
OT  - lymphoma
OT  - microRNA
OT  - single nucleotide polymorphism
OT  - susceptibility
EDAT- 2017/03/28 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/03/28 06:00
PHST- 2016/10/01 00:00 [received]
PHST- 2017/03/05 00:00 [revised]
PHST- 2017/03/23 00:00 [accepted]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - 10.1002/mc.22652 [doi]
PST - ppublish
SO  - Mol Carcinog. 2017 Aug;56(8):1945-1952. doi: 10.1002/mc.22652. Epub 2017 Apr 19.